Clinical trials
Hormone Receptor Positive / HER2-negative Breast Cancer clinical trials
Below are recruiting hormone receptor positive / her2-negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05332561RecruitingPhase 2
Personalized treatment after surgery for early breast cancer
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07380646RecruitingPhase 2
Leucogen to prevent low white blood cells from ribociclib in early breast cancer
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hangzhou, ZhejiangAges 18 years+ - NCT06385990RecruitingPhase 2
Utidelone plus Capecitabine for residual triple-negative breast cancer
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
Changsha, HunanAges 18–70 - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Newport Beach, CaliforniaAges 18 years+
Hear when a new Hormone Receptor Positive / HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hormone receptor positive / her2-negative breast cancer?
- Yes. Clin2 currently lists 100 recruiting hormone receptor positive / her2-negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hormone receptor positive / her2-negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hormone receptor positive / her2-negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Hormone-receptor-positive Breast Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive Breast Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.